British scientists have newly developed a transgenic rice rich in beta-carotene. The researchers believe that this type of rice helps to improve vitamin A deficiency in children in developing countries and the resulting blindness. The British media reported on the 29th that the GM rice grown by the Syngenta Biotech Company in the UK contains 20 times more beta-carotene than its predecessor. According to World Health Organization data, about 500,000 children worldwide are blind each year due to lack of vitamin A. Since the human body can convert beta-carotene to vitamin A, the long-term consumption of this new type of transgenic rice can prevent children from vitamin A deficiency and the resulting blindness. Syngenta has decided to provide the rice varieties to laboratories in Asia for free trials and promotion. The transgenic beta-carotene-rich rice was first cultivated in Switzerland five years ago, commonly known as "Gold Rice." However, the amount of beta-carotene that children consume through the daily intake of “golden rice” is not enough to produce sufficient amounts of vitamin A, and the newly-developed transgenic rice has been significantly improved, and its beta-carotene content has been greatly increased. However, some experts pointed out that the problem of vitamin A deficiency cannot be solved by relying solely on a genetically modified food. People lacking vitamin A are likely to lack other vitamins and minerals. Therefore, the nutritional structure of the patient must be thoroughly investigated.

Anti-Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic, etiology of inflammatory synovitis-based systemic disease. It is characterized by hand, small joints of the joints, symmetry, invasive joint inflammation, often associated with external organ involvement and serum rheumatoid factor positive, can lead to joint deformity and loss of function. According to statistics, the incidence of rheumatoid arthritis in women is 2 to 3 times that of men.It can occur at any age, high incidence of age 40 to 60 years old. People who has rheumatoid arthritis in the late, severe or long-term bedridden patients, due to combined infection, gastrointestinal bleeding, heart, lung or kidney disease can be crisis to life. The main purpose of treatment for Rheumatoid arthritis is to reduce the inflammation of the joints, inhibit the development of lesions and irreversible bone destruction, as far as possible to protect the function of joints and muscles, and ultimately achieve complete disease remission or low disease activity target. Treatment principles include 1. Patient education, 2. General treatment 3. Drug treatment 4. Immune purification 5. Functional exercise 6. Surgical treatment. Anti-Rheumatoid arthritis drug treatment mainly includes non-steroidal anti-inflammatory drugs, slow-acting anti-rheumatic drugs, immunosuppressive agents, immune and biological agents and botanicals. Over the past decade, the treatment of extra-articular lesions and the emergence of new therapies, so that the efficacy of rheumatoid arthritis has been significantly improved. Most patients with rheumatoid arthritis can get a good control or even complete remission.

Anti-Rheumatoid Arthritis,Rheumatoid Arthritis Diagnosis,Arthritis Treatment,Osteoarthritis Treatment,Best Treatment for Rheumatoid Arthritis,Rheumatoid Arthritis Treatment Drugs

Taizhou Volsen Chemical Co., Ltd. , https://www.volsenchem.com